(Q37845178)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21336546%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

title

Immunotherapy for EBV-associated malignancies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21336546%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21336546%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Paola Zanovello

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21336546%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Antonio Rosato

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21336546%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

2

Riccardo Turrini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21336546%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1

Anna Merlo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21336546%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

publication date

19 February 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21336546%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Hematology

23 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21336546%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

volume

93

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21336546%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21336546%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

page(s)

281-293

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21336546%20AND%20SRC:MED&resulttype=core&format=json

Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products.

23 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Functional inactivation of EBV-specific T-lymphocytes in nasopharyngeal carcinoma: implications for tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Galectin-1 mediated suppression of Epstein-Barr virus specific T-cell immunity in classic Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Cellular responses to viral infection in humans: lessons from Epstein-Barr virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

EBV-specific cytotoxic T lymphocytes protect against human EBV-associated lymphoma in scid mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Allogeneic T-cell therapy for Epstein-Barr virus-positive posttransplant lymphoproliferative disease: long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

T cell therapy of Epstein-Barr virus and adenovirus infections after hemopoietic stem cell transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Unsuccessful CTL transfusion in a case of post-BMT Epstein-Barr virus-associated lymphoproliferative disorder (EBV-LPD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Treatment of Epstein-Barr-virus-associated primary CNS B cell lymphoma with allogeneic T-cell immunotherapy and stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Epstein-Barr virus, cytokines, and inflammation: a cocktail for the pathogenesis of Hodgkin's lymphoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

The relationships between Epstein-Barr virus latent membrane protein 1 and regulatory T cells in Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Clinical effects of infusing anti-Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes into patients with severe chronic active EBV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Establishment of anti-Epstein-Barr virus (EBV) cellular immunity by adoptive transfer of virus-specific cytotoxic T lymphocytes from an HLA-matched sibling to a patient with severe chronic active EBV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Adoptive transfer of Epstein-Barr virus-specific cytotoxic T-lymphocytes for the treatment of angiocentric lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Epstein-Barr virus nuclear antigen 1-specific CD4+ T cells directly kill Epstein-Barr virus-carrying natural killer and T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Patients with Epstein Barr virus-positive lymphomas have decreased CD4(+) T-cell responses to the viral nuclear antigen 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Children with endemic Burkitt lymphoma are deficient in EBNA1-specific IFN-gamma T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Endogenous presentation of CD8+ T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Expansion of EBNA1-specific effector T cells in posttransplantation lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Epitope specificity and clonality of EBV-specific CTLs used to treat posttransplant lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Adoptive immunotherapy of cancer using CD4(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Virus-specific cytotoxic CD4+ T cells for the treatment of EBV-related tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Epstein-Barr virus nuclear antigen 1 evades direct immune recognition by CD4+ T helper cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

CD4+ T-cell clones recognizing human lymphoma-associated antigens: generation by in vitro stimulation with autologous Epstein-Barr virus-transformed B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Allo-HLA reactivity of virus-specific memory T cells is common

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

EBV-specific CD4+ T cell clones exhibit vigorous allogeneic responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Adoptive immunotherapy for cancer: building on success

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Adoptive T cell therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Cytolytic mechanisms and T-cell receptor Vbeta usage by ex vivo generated Epstein-Barr virus-specific cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Establishment and characterization of a bank of cytotoxic T lymphocytes for immunotherapy of epstein-barr virus-associated diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Epstein-Barr virus sustains tumor killers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Preemptive Therapy of EBV-Related Lymphoproliferative Disease after Pediatric Haploidentical Stem Cell Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0782-2

Immunotherapy for Hodgkin's disease.

21 January 2018

1 reference

12 December 2020

Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells.

1 reference

12 December 2020

Limiting-dilution analysis of the HLA restriction of anti-Epstein-Barr virus-specific cytolytic T lymphocytes

1 reference

12 December 2020

Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas

1 reference

12 December 2020

Immunotherapy for Epstein-Barr virus-associated cancers

1 reference

12 December 2020

Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease

1 reference

12 December 2020

Adoptive transfer of cytotoxic T lymphocytes for the treatment of transplant-associated lymphoma

1 reference

12 December 2020

Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.

1 reference

12 December 2020

Prompt versus preemptive intervention for EBV lymphoproliferative disease

1 reference

12 December 2020

Adoptive immunotherapy for EBV-associated malignancies

1 reference

12 December 2020

Adoptive transfer of antigen-specific T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants

1 reference

12 December 2020

Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients.

1 reference

12 December 2020

Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection

1 reference

12 December 2020

Correction of DiGeorge anomaly with EBV-induced lymphoma by transplantation of organ-cultured thymus and Epstein-Barr-specific cytotoxic T lymphocytes

1 reference

12 December 2020

10.1007/S12185-011-0782-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21336546%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference